Company news

Fate Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fate Therapeutics to Present at Upcoming December Investor Conferences

November 25, 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

November 17, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

November 17, 2024

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

November 11, 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

November 8, 2024

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

November 7, 2024

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

September 11, 2024

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

August 12, 2024

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

July 30, 2024

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2024

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 28, 2024

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 8, 2024

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 8, 2024

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

May 5, 2024

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 2, 2024

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

April 21, 2024

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

March 18, 2024

Fate Therapeutics to Present at Upcoming March Investor Conferences

February 29, 2024

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 25, 2024

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

January 7, 2024

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 12, 2023

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

November 7, 2023

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

October 24, 2023

Fate Therapeutics to Present at Upcoming September Investor Conferences

August 30, 2023

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

August 7, 2023

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

July 27, 2023

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 30, 2023

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

May 2, 2023

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

April 23, 2023

Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

February 27, 2023

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results

February 12, 2023

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

January 4, 2023

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

December 12, 2022

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

December 11, 2022

Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting

December 9, 2022

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting

December 9, 2022

Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors

November 6, 2022

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting

November 2, 2022

Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

November 2, 2022

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

October 23, 2022

Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immunotherapy of Cancer 37th Annual Meeting

October 4, 2022

Fate Therapeutics to Participate at Upcoming September Investor Conferences

September 1, 2022

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8αβ T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

August 8, 2022

Fate Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

August 2, 2022

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

July 24, 2022

Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer

June 29, 2022

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

June 27, 2022

Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

June 2, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.